6-fluoro-2',5'-dioxo-(2R,4'S)-spiro[3,4-dihydro-2H-chromene-4,4'-(1'H,2'H-imidazole)]-2-carboxamide

ID: ALA84060

Chembl Id: CHEMBL84060

PubChem CID: 449156

Max Phase: Preclinical

Molecular Formula: C12H10FN3O4

Molecular Weight: 279.23

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1

Standard InChI:  InChI=1S/C12H10FN3O4/c13-5-1-2-7-6(3-5)12(4-8(20-7)9(14)17)10(18)15-11(19)16-12/h1-3,8H,4H2,(H2,14,17)(H2,15,16,18,19)/t8-,12+/m1/s1

Standard InChI Key:  WAAPEIZFCHNLKK-PELKAZGASA-N

Alternative Forms

  1. Parent:

Associated Targets(Human)

AKR1B1 Tclin Aldose reductase (1404 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Akr1b1 Aldose reductase (4007 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AKR1A1 Aldehyde reductase (25 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 279.23Molecular Weight (Monoisotopic): 279.0655AlogP: -0.50#Rotatable Bonds: 1
Polar Surface Area: 110.52Molecular Species: NEUTRALHBA: 4HBD: 3
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 4#RO5 Violations (Lipinski):
CX Acidic pKa: 8.67CX Basic pKa: CX LogP: -0.68CX LogD: -0.70
Aromatic Rings: 1Heavy Atoms: 20QED Weighted: 0.60Np Likeness Score: -0.40

References

1. Oka M, Matsumoto Y, Sugiyama S, Tsuruta N, Matsushima M..  (2000)  A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2', 5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography.,  43  (12): [PMID:10882376] [10.1021/jm990502r]
2. El-Kabbani O, Darmanin C, Oka M, Schulze-Briese C, Tomizaki T, Hazemann I, Mitschler A, Podjarny A..  (2004)  High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor.,  47  (18): [PMID:15317464] [10.1021/jm0497794]
3. El-Kabbani O, Carbone V, Darmanin C, Oka M, Mitschler A, Podjarny A, Schulze-Briese C, Chung RP..  (2005)  Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.,  48  (17): [PMID:16107153] [10.1021/jm050412o]
4. Ferrari AM, Degliesposti G, Sgobba M, Rastelli G..  (2007)  Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.,  15  (24): [PMID:17870536] [10.1016/j.bmc.2007.08.019]

Source